Acarix Shares Begin Trading on the US-based OTCQB Market
Acarix, a leader in AI and acoustics-based cardiac diagnostics, has begun trading on the US-based OTCQB Market under the ticker symbol ACIXF. This move allows Acarix shares to be traded in USD alongside its existing Nasdaq First North Growth market listing in Stockholm. The OTCQB Market, operated by OTC Markets Group, serves as an alternative to Nasdaq New York and NYSE listings for 12,000 US and global securities.
CEO Aamir Mahmood expressed excitement about expanding the company's reach beyond the Stockholm listing, particularly as the US is Acarix's most important commercial market. The OTCQB listing is expected to increase accessibility to US capital markets and satisfy growing interest from US investors. Companies listed on OTCQB must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with US securities laws.
- Expanded market access through OTCQB listing in the US
- Potential for increased US investor interest and capital market accessibility
- Dual listing strategy (Stockholm and US) may enhance global investor base
- US is Acarix's most important commercial market, aligning with new listing
- None.
OTC Markets Group operates financial markets for 12,000 US and global securities. OTCQB is a trading platform in the US operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQB helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Companies on OTCQB meet high financial standards, follow best practice corporate governance, demonstrate compliance with US securities laws, and have a professional third-party sponsor introduction.
"We're excited to begin trading on the OTCQB Market in the US and expand the reach beyond our Nasdaq Stockholm listing. Acarix has a strong base of international shareholders and with the US being our most important commercial market, we now welcome the ability for more investors to join our journey," comments Aamir Mahmood, CEO of Acarix.
"We are pleased to welcome Acarix to the OTCQB Best Market," said Joe Coveney, Vice President of OTC Market Group's Corporate Services. "Acarix will trade alongside other leading life science and medical device companies that utilize a 'list local, trade global' strategy to leverage their home market filings and disclosures to publicly trade in the US and expand their global investor base."
About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least
Media Contact:
Jennifer Anderson
720-471-4625
jennifer.anderson@acarix.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/acarix-shares-begin-trading-on-the-us-based-otcqb-market-302196360.html
SOURCE Acarix
FAQ
What is Acarix's new stock ticker symbol on the OTCQB Market?
When did Acarix (ACIXF) begin trading on the OTCQB Market?
Why did Acarix choose to list on the OTCQB Market in addition to its Stockholm listing?
What are the benefits for Acarix (ACIXF) of cross-trading on the OTCQB Market?
